Status:
ACTIVE_NOT_RECRUITING
A Study of the Clinical Benefit of Tobramycin Inhalation Solution
Lead Sponsor:
Qianfoshan Hospital
Conditions:
Bronchiectasis
Cystic Fibrosis
Eligibility:
All Genders
Brief Summary
This project will use literature analysis, expert research, real-world data mining and other methods to investigate the current status of the application of antimicrobial aerosolized inhalation in hea...
Detailed Description
The current status of nebulised inhalation of antimicrobial drugs was examined by the main subject through literature search and expert research. The researchers selected patients who visited or were ...
Eligibility Criteria
Inclusion
- Bronchiectasis
- Patients with a past medical history or a diagnosis of bronchiectasis in the current case;
- Patients seen or admitted to the hospital from 1 January 2021 to 31 December 2023 (including outpatient, emergency, and inpatient);
- Case record of at least 1 course of treatment (continuous administration for 28 days) with tobramycin inhalation solution or other antibiotic nebulisation;
- Patients with a positive copper-green test at the first visit.
- Cystic fibrosis
- Patients with a past medical history or a diagnosis of cystic fibrosis in the current case;
- Patients who were seen or admitted to the hospital from 1 January 2021 to 31 December 2023 (including outpatient, emergency, and inpatient);
- Case record of at least 1 course of treatment (continuous administration for 28 days) with tobramycin inhalation solution or other antibiotic nebulisation;
- Patients with a positive copper-green test at the first visit.
- Multidrug-resistant bacterial lung infections
- Patients with a diagnosis of pulmonary infection;
- Patients admitted to the hospital from 1 January 2021 to 31 December 2023 (only inpatients were included);
- Case records with completion of at least 3 days of treatment with tobramycin inhalation solution or other antibiotic nebulisation;
- The patient tested positive for pathogens at least once during the period of medication.
Exclusion
- Bronchiectasis Patients with key information missing from the study, such as therapeutic agents, diagnostic information for bronchiectasis, etc.
- Cystic fibrosis Patients with cystic fibrosis, for which key information is missing, such as treatment medication, diagnosis of cystic fibrosis.
- Multidrug-resistant bacterial lung infections Patients hospitalized with severe pneumonia were missing key study information, such as laboratory tests not performed.
Key Trial Info
Start Date :
April 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 30 2024
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT06106789
Start Date
April 1 2023
End Date
October 30 2024
Last Update
October 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rui Yang,MD
Jinan, Shandong, China